// App-Quantinova.ai

6071 : A phase I study of the PI3K inhibitor buplarlisib (B) with concurrent chemoradiotherapy (CRT) in patients with high risk locally advanced squamous cell cancer of the head and neck (LASCCHN).

Researchers

Presenter

  • Jochen H. Lorch

Principal Investigators

  • Roy B. Tishler

  • Nicole Grace Chau

  • Glenn J. Hanna

  • Guilherme Rabinowits

  • Jonathan Daniel Schoenfeld

  • Danielle Nina Margalit

  • Anne M. O'Neill

  • Donald Annino

  • Laura A Goguen

  • Ravi Uppaluri

  • Ethan James Harris

  • Alec Kacew

  • Julian Huang

  • Laura Ma

  • Patricia Mchugh

  • Robert I. Haddad

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

  • Miami Cancer Institute, Miami, FL

  • Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA

  • Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

  • Dana-Farber Cancer Insitute and Department of Surgery, Division of Otolaryngology, Brigham and Women's Hospital, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Cisplatin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT02113878

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved